National Vision Holdings, Inc. (EYE) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-07-04..
- Stock-based compensation / revenue · 12 months: Value 1.22%; Formula and calculation Share-based compensation / revenue. Period ending 2026-07-04..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-07-04; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-07-04. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | 1.22% | Share-based compensation / revenue. Period ending 2026-07-04. $24.74M ÷ $2.03B × 100 ≈ 1.22% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | |
| Revenue | 2.03B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 24.74M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 82.78M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-07-04 | (m) | $2.03B | $24.74M | $82.78M | (m) | (m) | 1.22% | (m) | (m) |
| 2026-04-04 | (m) | $2.02B | $23.68M | $77.93M | (m) | (m) | 1.17% | (m) | (m) |
| 2026-01-03 | (m) | $1.99B | $23.69M | $58.83M | (m) | (m) | 1.19% | (m) | (m) |
| 2025-09-27 | (m) | $1.92B | $22.77M | $26.62M | (m) | (m) | 1.18% | (m) | (m) |
| 2025-06-28 | (m) | $1.89B | $21.80M | $8.19M | (m) | (m) | 1.16% | (m) | (m) |
| 2025-03-29 | (m) | $1.85B | $21.27M | $-7.66M | (m) | (m) | 1.15% | (m) | (m) |
| 2024-12-28 | (m) | $1.82B | $16.71M | $-10.36M | (m) | (m) | 0.92% | (m) | (m) |
| 2024-09-28 | (m) | $2.18B | $16.91M | $-68.52M | (m) | (m) | 0.78% | (m) | (m) |
| 2024-06-29 | (m) | $2.16B | $17.63M | $-56.15M | (m) | (m) | 0.81% | (m) | (m) |
| 2024-03-30 | (m) | $2.15B | $18.32M | $-51.50M | (m) | (m) | 0.85% | (m) | (m) |
| 2023-12-30 | (m) | $2.13B | $20.17M | $-46.83M | (m) | (m) | 0.95% | (m) | (m) |
| 2023-09-30 | (m) | $2.09B | $18.01M | $-43.35M | (m) | (m) | 0.86% | (m) | (m) |
| 2023-07-01 | (m) | $2.06B | $15.93M | $46.61M | (m) | (m) | 0.77% | (m) | (m) |
| 2023-04-01 | (m) | $2.04B | $14.09M | $57.26M | (m) | (m) | 0.69% | (m) | (m) |
| 2022-12-31 | (m) | $2.01B | $13.51M | $61.27M | (m) | (m) | 0.67% | (m) | (m) |
| 2022-10-01 | (m) | $2.01B | $11.56M | $79.01M | (m) | (m) | 0.57% | (m) | (m) |
| 2022-07-02 | (m) | $2.03B | $12.06M | $114.36M | (m) | (m) | 0.59% | (m) | (m) |
| 2022-04-02 | (m) | $2.07B | $15.63M | $150.82M | (m) | (m) | 0.75% | (m) | (m) |
| 2022-01-01 | (m) | $2.08B | $14.89M | $174.94M | (m) | (m) | 0.72% | (m) | (m) |
| 2021-10-02 | (m) | $2.10B | $16.27M | $223.88M | (m) | (m) | 0.78% | (m) | (m) |
| 2021-07-03 | (m) | $2.07B | $15.50M | $227.97M | (m) | (m) | 0.75% | (m) | (m) |
| 2021-04-03 | (m) | $1.78B | $11.63M | $131.54M | (m) | (m) | 0.66% | (m) | (m) |
| 2021-01-02 | (m) | $1.71B | $10.74M | $87.01M | (m) | (m) | 0.63% | (m) | (m) |
| 2020-09-26 | (m) | $1.62B | $10.16M | $38.47M | (m) | (m) | 0.63% | (m) | (m) |
| 2020-06-27 | (m) | $1.56B | $13.40M | $-5.21M | (m) | (m) | 0.86% | (m) | (m) |
| 2020-03-28 | (m) | $1.73B | $11.79M | $58.09M | (m) | (m) | 0.68% | (m) | (m) |
| 2019-12-28 | (m) | $1.72B | $12.67M | $73.58M | (m) | (m) | 0.73% | (m) | (m) |
| 2019-09-28 | (m) | $1.68B | $18.03M | $45.83M | (m) | (m) | 1.07% | (m) | (m) |
| 2019-06-29 | (m) | $1.63B | $22.54M | $32.63M | (m) | (m) | 1.38% | (m) | (m) |
| 2019-03-30 | (m) | $1.59B | $22.32M | $35.90M | (m) | (m) | 1.40% | (m) | (m) |
| 2018-12-29 | (m) | $1.54B | $20.94M | $42.35M | (m) | (m) | 1.36% | (m) | (m) |
| 2018-09-29 | (m) | $1.50B | $15.76M | $61.40M | (m) | (m) | 1.05% | (m) | (m) |
| 2018-06-30 | (m) | $1.46B | $6.28M | $79.18M | (m) | (m) | 0.43% | (m) | (m) |
| 2018-03-31 | (m) | $1.41B | $5.64M | $67.16M | $53.36M | (m) | 0.40% | 1.26× | Reported |
| 2017-12-30 | (m) | $1.38B | $5.15M | $67.24M | $55.54M | (m) | 0.37% | 1.21× | Reported |
| 2017-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-07-01 | (m) | $1.29B | (m) | $64.46M | (m) | (m) | (m) | (m) | (m) |
| 2017-04-01 | (m) | $1.24B | (m) | $66.42M | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | $1.20B | $4.29M | $66.38M | $39.09M | (m) | 0.36% | 1.70× | Reported |
| 2016-10-01 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-07-02 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-04-02 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-01-02 | (m) | $1.06B | $6.63M | $44.68M | $36.74M | (m) | 0.62% | 1.22× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STAAR SURGICAL CO (STAA) | United States | $0.957B | 362.70 |
| RxSight, Inc. (RXST) | United States | $0.197B | |
| Innovative Eyewear Inc (LUCY) | United States | $0.008B | |
| Warby Parker Inc. (WRBY) | United States | $2.970B | |
| Bausch & Lomb Corp (BLCO) | Canada | $6.008B | -34.58 |
| COOPER COMPANIES, INC. (COO) | United States | $10.533B | 24.09 |